Table 2.
Lifetime Soy/Isoflavone Administration.
| Species | Isoflavone Diet/Timing | Tumor Inducer | Main Finding | Refs |
|---|---|---|---|---|
| rat | ISP, gestation day 4-EOS1 | 1 injection of 50 mg/kg body weight NMU at PND50 | Tumor incidence reduced, and latency increased in SPI group; tumor multiplicity not affected | [93] |
| rats | ISP, gestation day 4-EOS | 1 injection of 50 mg/kg body weight NMU at PND51 | No significant differences in tumor incidence or multiplicity | [94] |
| mice | 90 mg/kg Prevastein (46.19% wt/wt isoflavones) 2 weeks prior to mating-EOS | MMTV-neu on high fat diet with either corn oil or fish oil | Decreased tumor incidence and increased tumor latency in isoflavone group with corn oil but no significant differences in group with fish oil | [96] |
| mice | Soy containing 4RF21, breeding-weaning and then 4RF21, SPI or isoflavone poor concentrate, PND21-EOS | MMTV-neu | No difference in tumor incidence | [95] |
| mice | 20% ISP, breeding-EOS | MTB-IGFIR (IGF-IR induced at PND45 or PND100) | Tumor onset reduced, and incidence increased in ISP group | [66] |
1 EOS = end of study; PND = post-natal days; ISP = isolated soy protein; NMU = N-methyl-N-nitrosourea.